The company said, "For the fiscal year ending January 31, 2024, management expects revenue of approximately $950 million to $970 million and Adjusted EBITDA of approximately 33-34% of revenue. These amounts assume an average annualized yield on HSA cash of approximately 2.25%."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HQY:
- HealthEquity Reports Third Quarter Ended October 31, 2022 Financial Results
- HealthEquity price target raised to $75 from $70 at RBC Capital
- HealthEquity Sets Date to Announce Third Quarter Results
- HealthEquity Ranked No. 1 HSA Provider on its 20th Anniversary, Releases New Edition of the HSA Guidebook